HC Wainwright & Co. Maintains Buy on PMV Pharma, Lowers Price Target to $29
Benzinga Newsdesk 3 years ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Robert Burns maintains PMV Pharma (NASDAQ:PMVP) with a Buy and lowers the price target from $35 to $29.
HC Wainwright & Co. analyst Robert Burns maintains PMV Pharma (NASDAQ:PMVP) with a Buy and lowers the price target from $35 to $29.